Wu Feng Liang

PVP ), ( PKP ), ( MIS-TLIF ), ( MIDLF ), ( ULRD,ULBD ) ( endo-TLIF ).,. Ⅳ., 、,,;.:, ( PVP ), ( PKP ), ( MIS-TLIF ), ( MIDLF ), ( ULBD ) ( endo-TLIF ).: 1998 9 － 2003 7:, 2003 9 － 2008 7:,: 2003.08 － 2008.8 2008.8 － 2014.07 2014.7 － 2015.8- 2011.11-2011.12 AO 2013.6-2013.7 fellowship Norton Leatherman Spine Center,USA Rolando.M.Puno 2014.9.21-2014.9.27 Trousseau La Roche-guvon, France 2015.7.5-2015.7.31 AO fellowship Rizzoli Orthopedic Institute,Italy Stefano Boriani 2016.5.1-2016.11.30 fellowship ( Massachusatte General Hospital,MGH ),USA Joseph. H.Schwab 2019.7.29-2020-8.14 “ ” AOSpine 1): ( CBT ) ( TT ) 2018 5 2): “ ” 2020 70 3):“ ” “ ” 2020 16.77 4): 2019 300 5): IASPP 2017.1-12 12 6): 2015.1-2018.12 72 7): 8): 2025.12-2028.12 5200 2008,, 2011 2013 2014 2017-2019, 2021-2024 6 “ ” 2020 MRI 2008, 7 2.., 2013, 45(5): 950-55. 3. Fengliang Wu, et al. Cervical Neurofibromatosis with tetraplegia: management by cervical suspensory traction. Spine: 2012; 37(14), 858–62 4. Feng Liang Wu, et al. Polyostotic dysplasia involving the thoracic spine with myelopathy: case report and review of the literature. The Spine Journal: 2014 Jan 1;14(1):e11-5. 5. Feng Liang Wu, et al. Fibrous dysplasia of the mobile spine: report of 8 cases and review of the literature. Spine: 2013; Nov 1; 38(21), 2016-22. 6.Feng Liang Wu, et al. Risk factors associated with upper extremity palsy after expansive open-door laminoplasty for cervcal myelopathy. The Spine Journal: 2014; Jun 1; 909-915 7.,2019,(12):1080-1087. 8. 3, 2020; 4: 185-191. 9.Two-Year Outcomes of Midline lumbar Fusion Versus Minimally Invasive Transforaminal Lumbar Interbody Fusion in the treatment of L4-L5 degenerative disease, 2020, 11 Biomedical and Environmental Sciences. IF=2.656(2019) 10. MR 2021 ( 38 ): 178-185.